Metabolic and epigenetic abnormalities cause hepatic fibrogenesis in metabolic dysfunction–associated steatohepatitis model mice
Journal of Biological Chemistry · 2026
DOI: 10.1016/j.jbc.2025.110959 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026. Verfasst von Atsushi Miura und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Life Sciences, Nihon University Graduate School of Bioresource Sciences, Fujisawa, Kanagawa, Japan. Hauptthemen laut MEDLINE: Liver Cirrhosis, Epigenesis, Genetic, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
The prevalence rates of liver-related metabolic syndrome, metabolic dysfunction-associated steatotic liver disease, and the consequent metabolic dysfunction-associated steatohepatitis (MASH) are increasing worldwide. There is a well-established and reproducible choline-deficient l-amino acid-defined high-fat diet (CDAHFD)-induced MASH model, but the cause of the hepatic fibrogenesis in this model is unclear. We evaluated the phenotypic changes associated with hepatic fibrogenesis in CDAHFD-fed mice using RNA sequencing, GC-MS, and LC-MS-based metabolic analyses. A time-series liver transcriptomic analysis revealed inflammation and activated matrix remodeling within 1 week in the CDAHFD-fed mouse liver. Also, metabolomic analysis revealed increased activity in the pentose phosphate pathway, an elevated S-adenosylmethionine (SAM) level, and an increased SAM/S-adenosylhomocysteine (SAH) ratio in the CDAHFD-fed mouse liver. The increased SAM/SAH ratio positively correlated with hepatic Tgfb1 mRNA expression. Moreover, the SAM synthesis inhibitor cycloleucine suppressed the activation of fibrogenic signaling and subsequent fibrogenesis in the liver. In the Gubra-amylin liver nonalcoholic steatohepatitis diet-fed ob/ob mouse model of MASH, increases in the SAM/SAH ratio, upregulation of fibrosis-related genes, and alterations in H3 histone methylation were observed, similar to those seen in the CDAHFD-fed MASH model. This study reveals the transcriptomic and metabolomic features of the MASH model mice and proposes a novel link between hepatic fibrogenesis and epigenetic histone modification in the context of metabolic dysfunction-associated steatotic liver disease/MASH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Applied Life Sciences, Nihon University Graduate School of Bioresource Sciences, Fujisawa, Kanagawa, Japan.
- Department of Chemistry and Life Science, Nihon University College of Bioresource Sciences, Fujisawa, Kanagawa, Japan.
- Department of Applied Life Sciences, Nihon University Graduate School of Bioresource Sciences, Fujisawa, Kanagawa, Japan; Department of Chemistry and Life Science, Nihon University College of Bioresource Sciences, Fujis…
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Miura, A., Ikeda, S., Kono, Y., Kawate, K., Hosono, T., & Seki, T. (2026). Metabolic and epigenetic abnormalities cause hepatic fibrogenesis in metabolic dysfunction–associated steatohepatitis model mice. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.110959
Vancouver
Miura A, Ikeda S, Kono Y, Kawate K, Hosono T, Seki T. Metabolic and epigenetic abnormalities cause hepatic fibrogenesis in metabolic dysfunction–associated steatohepatitis model mice. Journal of Biological Chemistry. 2026. doi:10.1016/j.jbc.2025.110959
BibTeX
@article{Miura2026,
author = {Miura, Atsushi and Ikeda, Shiori and Kono, Yuki and Kawate, Keigo and Hosono, Takashi and Seki, Taiichiro},
title = {Metabolic and epigenetic abnormalities cause hepatic fibrogenesis in metabolic dysfunction–associated steatohepatitis model mice},
journal = {Journal of Biological Chemistry},
year = {2026},
doi = {10.1016/j.jbc.2025.110959}
}
EUVIMED